Esperion Therapeutics, Inc.

Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.

ESPR | NDAQ

Overview

Corporate Details

ISIN(s):: US29664W1053
LEI:
Country:: United States of America
Address:: 3891 RANCHERO DRIVE, SUITE 150, 48108 ANN ARBOR
Website:: https://www.esperion.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Esperion Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. The company's core products are based on a novel mechanism of action, being the first to bring an ATP Citrate Lyase (ACLY) inhibitor to market. These treatments are approved in the U.S. and Europe, addressing significant unmet needs in cardiovascular disease management, particularly for patients with statin intolerance. Esperion utilizes commercial partnerships to enable global access to its medicines while advancing a pipeline focused on next-generation inhibitors for life-threatening diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Esperion Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Esperion Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Esperion Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
AVADEL PHARMACEUTICALS PLC Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.	United States of America	AVDL
Avidity Biosciences, Inc. Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.	United States of America	RNA
Axsome Therapeutics, Inc. Biopharma company developing novel therapies for central nervous system (CNS) conditions.	United States of America	AXSM
AYTU BIOPHARMA, INC Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.	United States of America	AYTU
Azitra, Inc. Developing engineered proteins and live biotherapeutics for rare skin diseases.	United States of America	AZTR
Bachem Holding AG A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.	Switzerland	BANB
Barinthus Biotherapeutics plc. Develops T cell immunotherapies for autoimmune and chronic infectious diseases.	United States of America	BRNS
Basilea Pharmaceutica AG Develops & commercializes anti-infectives for severe bacterial & fungal infections.	Switzerland	BSLN
Bausch Health Companies Inc. Develops, manufactures, and markets pharmaceuticals, OTCs, and medical devices globally.	United States of America	BHC
Bavarian Nordic A biotech firm developing and manufacturing life-saving vaccines for travel and public health.	Denmark	BAVA